<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588026</url>
  </required_header>
  <id_info>
    <org_study_id>AK580</org_study_id>
    <nct_id>NCT03588026</nct_id>
  </id_info>
  <brief_title>Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576</brief_title>
  <acronym>CAPSTONE</acronym>
  <official_title>Investigational Product ; Coversin. Phase III Safety and Efficacy in Three-Part, Two-Arm, Randomised Open Label Evaluation in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AKARI Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AKARI Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      rVA576 for patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      rVA576, a small protein complement C5 inhibitor which prevents the cleavage of C5 by C5
      convertase into C5a and C5b, will be used in an open label, non-comparative clinical trial in
      patients with PNH.

      Patients will be treated with rVA576 by daily subcutaneous injection in order to determine
      the safety and efficacy of the drug in these circumstances.

      If satisfactory control of the PNH is achieved, and at the discretion of the Principal
      Investigator (PI), patients will have the option of remaining on rVA576 and being entered
      into the long term follow-up study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HB (Haemoglobin) stabilisation rate and the avoidance of packed red blood cells (PRBC) transfusions</measure>
    <time_frame>9 months</time_frame>
    <description>Haemoglobin stabilisation rate defined as haemoglobin greater than the set point for each patient during the pre-study randomisation period and the avoidance of PRBC transfusions during the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of units of packed red blood cells (PRBC) transfused</measure>
    <time_frame>Day 1 to Day 180</time_frame>
    <description>Number of units of packed red blood cells (PRBC) transfused from Baseline Day 1 to Day 180</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who achieve transfusion avoidance</measure>
    <time_frame>Day 1 to Day 180</time_frame>
    <description>Percentage of patients who achieve transfusion avoidance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in (QOl) Quality of Life score</measure>
    <time_frame>Day 1 to Day 180</time_frame>
    <description>Change in Quality of Life score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (LDH)</measure>
    <time_frame>Day 1 to Day 180</time_frame>
    <description>AUC (Area under the curve) (LDH) Lactate Dehydrogenase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CH50</measure>
    <time_frame>Day 1 to Day 180</time_frame>
    <description>CH50 (Classical haemolytic 50% lysis)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria (PNH)</condition>
  <arm_group>
    <arm_group_label>Arm 1 - 9 months of treatment (rVA576 plus SOC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 months (SOC plus rVA576), Followed by a further 3 months of (SOC plus rVA576).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - 6 months on SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 months on SOC only. Followed by 3 months (SOC plus rVA576).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rVA576</intervention_name>
    <description>6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.</description>
    <arm_group_label>Arm 1 - 9 months of treatment (rVA576 plus SOC)</arm_group_label>
    <arm_group_label>Arm 2 - 6 months on SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care (SOC)</intervention_name>
    <description>6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.</description>
    <arm_group_label>Arm 1 - 9 months of treatment (rVA576 plus SOC)</arm_group_label>
    <arm_group_label>Arm 2 - 6 months on SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing to give informed consent to treatment with rVA576

          2. Diagnosed with paroxysmal nocturnal haemoglobinuria (PNH)

          3. Have not received any complement inhibitor within the 4 months prior to screening

          4. ≥ 18 years of age at the time of screening

          5. Weight ≥50kg

          6. Complete transfusion medical history for 12 months

          7. Transfusion dependent

          8. LDH ≥1.5 x the ULN

          9. Willing to receive appropriate prophylaxis against Neisseria meningitidis infection,
             by both immunisation and continuous or intermittent antibiotics

         10. Willing to avoid prohibited medications such as other complement inhibitors and
             chemotherapeutic agents

         11. Patients must agree to avoid pregnancy and fathering children from the time of signing
             the Informed Consent Form until 90 days after the last dose of rVA576.

         12. Patients who are on erythropoietin and/or immunosuppressant treatment should be on
             stable doses for at least 6 months.

         13. Patients who are taking systemic corticosteroids should be on a stable dose for at
             least 4 weeks.

         14. Patients on anticoagulant therapy should be well-controlled prior to entry.

         15. Patients taking iron and/or folic acid supplements should be on a stable dose for at
             least 4 weeks

        Exclusion Criteria:

          1. Patients whose mean haemoglobin level over the previous 12 months prior to screening
             was greater than 105 g/L (10.5g/dL)

          2. Severe bone marrow failure

          3. Patients with a platelet count of ≤ 70 x 109/L

          4. Patients with known or suspected acquired somatic mutations affecting the bone marrow
             (e.g. acute myeloid leukaemia) which may be associated with PNH

          5. Chemotherapy within 3 months of screening visit

          6. History of recurrent bacterial infections or suspicion of active bacterial infections
             requiring antibiotic therapy

          7. Planned or actual pregnancy or breast feeding (females)

          8. Known allergy to ticks or severe reaction to arthropod venom (e.g. bee or wasp venom)

          9. Unresolved N. meningitidis infection.

         10. Patients who are not willing to receive adequate immunisation against N. meningitidis
             unless, in the opinion of the investigator, the risks of delaying therapy outweigh the
             risks of developing a meningococcal infection

         11. Impaired hepatic function unless, in the opinion of the investigator, the risks of
             delaying therapy outweigh the risks of treatment in the presence of impaired hepatic
             function

         12. Patients with a glomerular filtration rate (GFR) of &lt;30mL/min/1.73m2 unless, in the
             opinion of the investigator, the risks of delaying therapy outweigh the risks of
             treatment in the presence of impaired renal function

         13. Participation in other clinical trials within 4 weeks of signing the consent form

         14. History of active systemic autoimmune diseases.

         15. Any other systemic disorders that could interfere with the evaluation of the study
             treatment

         16. Failure to comply with protocol requirements

         17. Known Hepatitis B or Hepatitis C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrius Degulys, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vilnius University Hospital Santaros Klinikos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wynne Weston-Davies</last_name>
    <phone>020 8004 0967</phone>
    <phone_ext>0268</phone_ext>
    <email>wynne.weston-davies@akaritx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miles Nunn</last_name>
    <phone>020 8004 0267</phone>
    <phone_ext>0267</phone_ext>
    <email>miles.nunn@akaritx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Almaty City Hospital No.7</name>
      <address>
        <city>Almaty</city>
        <state>Microdistrict Kalkaman</state>
        <zip>050006</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalimantas Glodenis</last_name>
      <phone>+370 604 666 20</phone>
      <email>Dalimantas.Glodenis@pharm-olam.com</email>
    </contact>
    <investigator>
      <last_name>Gulzhan Sabyrbayeva, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santaros Klinikos , Santariškių St. 2, LT-08661,</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalimantas Glodenis</last_name>
      <phone>+370 604 666 20</phone>
      <email>Dalimantas.Glodenis@pharm-olam.com</email>
    </contact>
    <investigator>
      <last_name>Andrius Degulys, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kelaniya, Faculty of Medicine, Thalagolla Road</name>
      <address>
        <city>Colombo</city>
        <zip>Ragama/11010</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arka Moitra</last_name>
      <phone>+91-80-6718 2214</phone>
      <email>arka.moitra@pharm-olam.com</email>
    </contact>
    <investigator>
      <last_name>Senani Williams, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
    <country>Lithuania</country>
    <country>Sri Lanka</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

